Fraser Clinical Trials, Inc.

New Westminster, British Columbia V3L 3W4

0 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndrome, Atrial Fibrillation, Cardiovascular Diseases, Cardiovascular Risk, Chronic Kidney Disease, Colitis, Ulcerative, Crohn's Disease, Dyslipidemia, Heart Diseases, Heart Failure, Heart Failure, Congestive, High Bleeding Risk

Studies at this site

• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study of Ponsegromab in People With Heart Failure — Stopped early
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants — Completed
• LEADERS FREE II: BioFreedom™ Pivotal Study — Running, not enrolling
• A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation — Stopped early
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early
• Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function — Completed